<DOC>
	<DOCNO>NCT01421589</DOCNO>
	<brief_summary>Obesity associate reduced growth hormone ( GH ) secretion . Reduced GH secretion obesity associate increase cardiovascular disease risk . However , yet know reduced GH increase cardiovascular disease risk obesity . The investigator hypothesize reduce GH contribute dysfunction mitochondrion . Therefore , investigator hypothesize treatment obese subject reduce GH secretion GH improve mitochondrial function improvement mitochondrial function contribute , part , effect GH improve metabolic parameter obesity . The investigator propose study skeletal muscle mitochondrion obese subject reduce GH secretion use magnetic resonance spectroscopy muscle biopsy treatment GH .</brief_summary>
	<brief_title>Growth Hormone Treatment Phosphocreatine Recovery Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Phosphocreatine</mesh_term>
	<criteria>1 . Men age 1860 year old 2 . BMI ≥ 30 kg/m2 3 . Waist circumference ≥ 102 cm 4 . Peak GH value ≤ 4.2 μg/l standard GHRHarginine stimulation test 1 . Obesity due know secondary cause ( Cushing 's syndrome , hypothyroidism , etc ) history gastric bypass procedure . 2 . Subjects know history diabetes , fast blood sugar &gt; 125 mg/dl use antidiabetic drug . 3 . Use Aspirin , Clopidogrel ( Plavix ) , Warfarin ( Coumadin ) anticoagulants 4 . Subjects testosterone , glucocorticoid , anabolic steroid , GHRH , GH IGF1 within 3 month enrollment . 5 . Changes lipid lower antihypertensive regimen within 3 month screen 6 . History pituitary tumor , hypopituitarism , pituitary surgery , pituitary/brain radiation traumatic brain injury condition know affect GH axis . 7 . Severe chronic illness include HIV , active malignancy history colon cancer . 8 . Hemoglobin &lt; 9.0 g/dL , SGOT &gt; 2.5 x upper limit normal , Creatinine &gt; 1.5 mg/dL , PSA &gt; 5 ng/ml . 9 . Subject currently enrol another investigational device drug trial ( ) , subject receive investigational agent ( ) within 28 day baseline visit . 10 . Any condition judge patient 's physician cause clinical trial detrimental patient . 11 . Contraindications MRI scanning .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Growth hormone</keyword>
	<keyword>GH</keyword>
	<keyword>Obesity</keyword>
	<keyword>Mitochondrial function</keyword>
	<keyword>reduced growth hormone secretion</keyword>
</DOC>